MANCHESTER KEITH S Insider Trading Activity

Average Profitability
<0.0001%
Insider Buys Quantity
0
Insider Buys Sum
$0
Insider Sells Quantity
6
Insider Sells Sum
$141.45M

Insider Activity of MANCHESTER KEITH S

According to the SEC Form 4 filings, MANCHESTER KEITH S, being in a position of

  1. director at Roivant Sciences Ltd.,
    оver the last 12 months, has bought 0 shares, and sold 5858561 share for $154.47M,
    over all time since 2022-11-10, has bought 0 shares, and sold 25025217 shares for $295.88M.

Biography of MANCHESTER KEITH S

No biography is available at this moment.

Statistics of Insider Transactions Last Year

Amount of Insider Buys and Sells by Stocks

Buys
$000
Sells
$154,472,3079100

Comparison of Insiders on Amount of Buys and Sells

2026-06-30SaleRoivant Sciences Ltd.
ROIV
director
212,380
0.0301%
$35.44$7.53M+1.13%
2026-06-29SaleRoivant Sciences Ltd.
ROIV
director
800,000
0.1107%
$34.55$27.64M+3.02%
2026-06-26SaleRoivant Sciences Ltd.
ROIV
director
625,783
0.0868%
$34.00$21.28M+5.02%
2026-02-13SaleRoivant Sciences Ltd.
ROIV
director
375,784
0.0526%
$26.50$9.96M+26.09%
2026-02-12SaleRoivant Sciences Ltd.
ROIV
director
425,000
0.0594%
$26.75$11.37M+24.62%
2026-02-11SaleRoivant Sciences Ltd.
ROIV
director
425,000
0.0591%
$26.67$11.33M+24.33%
2025-12-17SaleRoivant Sciences Ltd.
ROIV
director
777,332
0.1136%
$23.07$17.94M+30.51%
2025-12-16SaleRoivant Sciences Ltd.
ROIV
director
917,282
0.1324%
$23.04$21.13M+28.95%
2025-11-19SaleRoivant Sciences Ltd.
ROIV
director
1.3M
0.1859%
$20.23$26.3M+44%
2024-09-25SaleRoivant Sciences Ltd.
ROIV
director
134,948
0.018%
$11.77$1.59M-3.4%
2024-09-24SaleRoivant Sciences Ltd.
ROIV
director
368,052
0.0486%
$11.63$4.28M-2.74%
2024-08-14SaleArbutus Biopharma Corporation
ABUS
director
8,846
0.0048%
$3.69$32,637-7.34%
2023-09-28SaleRoivant Sciences Ltd.
ROIV
director
6.9M
0.8144%
$11.55$79.65M-13.71%
2022-11-10SaleRoivant Sciences Ltd.
ROIV
director
3.92M
0.5042%
$4.75$18.63M+74.52%
2022-11-10SaleRoivant Sciences Ltd.
ROIV
director
7.85M
1.0085%
$4.75$37.26M+74.52%
Total: 15
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.